Compounded vs Brand-Name Semaglutide: A Clinical Analysis

What 'compounded semaglutide' actually is

Compounded semaglutide is made with the drug in Wegovy and Ozempic (semaglutide, a 31-amino-acid peptide developed and patented by Novo Nordisk), not the same product. The difference is who manufactures the finished drug product and under what regulatory framework.

Wegovy and Ozempic are manufactured by Novo Nordisk under FDA-approved New Drug Applications (NDA 215256 for Wegovy, NDA 209637 for Ozempic). The finished product is a pre-filled pen device with a specific dose strength, excipient profile, sterility validation, and packaging that has been reviewed by the FDA. Compounded semaglutide is prepared by 503A pharmacies for an individual patient’s prescription. 503B outsourcing facilities make office stock under a different framework, but in April 2026 FDA proposed not to add semaglutide to the 503B bulks list; no final decision had been published as of October 15, 2026. It is made with the drug in Wegovy and Ozempic, not the same product: the finished product, formulation, concentration, and packaging differ.

FDA position (April 2026 guidance)

The FDA's April 2026 guidance document on GLP-1 compounding clarified several points. First, a 503A pharmacy may compound semaglutide from bulk active ingredient for a patient-specific prescription when state law allows, when the API comes from an FDA-registered facility, and when the pharmacy meets applicable USP standards (USP 797 for sterile compounding, USP 800 for hazardous drug handling). In April 2026 FDA proposed not to add semaglutide to the 503B bulks list; no final decision had been published as of October 15, 2026.

The guidance discouraged compounding of identical-to-commercially-available formulations when commercial supply is consistent, citing the 'essentially a copy' provision of FDA Modernization Act amendments. However, dose strengths, concentrations, or formulation modifications not commercially available (for example, lower-concentration vials for sensitive patients, or combinations with B12) generally remain compoundable.

Compounding pharmacies must provide finished product to a named individual patient with a valid prescription (503A) and may not advertise specific drug products in a way that resembles commercial marketing. The FDA's authority to enforce these provisions varies by state.

Active pharmaceutical ingredient quality

API quality is the most consequential variable in compounded versus branded comparison. FDA-registered API manufacturers (which include facilities in the United States, China, India, and several European countries) produce semaglutide that meets pharmacopeial specifications for purity, potency, and impurity profile. A USP monograph for semaglutide was finalized in 2024.

Quality differentiation exists between API suppliers. Tier-1 suppliers manufacture under DMF (drug master file) registration and ship with full certificates of analysis including HPLC chromatograms, mass spectrometry verification, and endotoxin testing. Tier-2 suppliers may meet basic potency specifications without the same depth of impurity characterization. Compounding pharmacies sourcing from FDA-registered DMF-holders provide higher assurance than those sourcing from less-documented channels.

The most reliable compounding pharmacies publish their API source and audit reports. Patients should ask their compounding pharmacy or telehealth provider for this information; 503A pharmacies that decline to disclose API source warrant caution.

Clinical evidence base

There is no FDA-approved randomized clinical trial of compounded semaglutide. The clinical evidence base for the molecule comes from the brand-name trials (STEP, SUSTAIN, PIONEER, SELECT programs). If the API is chemically identical and the formulation produces equivalent bioavailability, clinical effects should be equivalent — but this assumption has limits.

Real-world evidence from compounded semaglutide use is limited but growing. Single-arm registry data from telehealth providers using 503A pharmacies show weight-loss trajectories broadly similar to STEP-1 (mean 10% to 15% loss at 6 to 12 months in adherent patients), though direct comparison is confounded by patient selection, lifestyle support intensity, and outcome ascertainment.

Adverse event profiles in compounded use appear similar to branded based on FDA Adverse Event Reporting System (FAERS) data, with the caveat that compounded products may be underreported. Serious safety signals specific to compounded products have included a small number of contamination-related events (concentration errors, microbial contamination) that did not occur in branded supply.

Concentration errors and dosing safety

One difference between branded and compounded supply is dose-delivery format. Wegovy comes in pre-filled pens with fixed doses (0.25, 0.5, 1.0, 1.7, and 2.4 mg). Compounded supply often comes in multi-dose vials at concentrations such as 2.5 mg/mL, 5 mg/mL, or 10 mg/mL, requiring patient self-administration of measured volumes with a syringe.

This shift to volume-based dosing has been associated with dose errors in the early period of widespread compounded use. The most common errors include 10-fold overdose (drawing 0.5 mL of 5 mg/mL solution thinking it was 0.5 mg, when it was actually 2.5 mg), and dose drift over time as patients become casual about measurement. Compounding pharmacies and telehealth providers have responded with clearer labeling, dosing apps, and patient education, but the underlying safety concern remains.

Patients using compounded semaglutide should confirm the concentration of their vial, use a consistent syringe size (typically a 0.3 mL insulin syringe for low doses, or a 1 mL tuberculin syringe for higher doses), and double-check dose volume against the prescriber's instructions every time.

Pharmacy quality differentiation (503A vs 503B)

503A pharmacies compound for individual patients with a valid prescription. They are licensed and inspected by state boards of pharmacy. Most operate under USP 797 (sterile compounding) standards.

503B outsourcing facilities compound at larger scale and ship office stock to clinicians. They are licensed and inspected by the FDA, must operate under cGMP-like (current Good Manufacturing Practice) standards, and are required to file adverse event reports.

503B pharmacies are subject to substantially stricter quality requirements than 503A. For the same molecule, 503B-sourced compounded products provide more assurance of consistency and contamination control. However, 503A flexibility allows for personalized formulations (B12 combinations, modified concentrations) that 503B cannot easily provide.

When evaluating a compounded semaglutide provider, ask: (1) Is the pharmacy 503A or 503B? (2) What is the pharmacy name and license number? (3) Has the pharmacy had any FDA Form 483 observations or warning letters? (4) Where does the API source from? Providers that decline to answer warrant skepticism.

Related editorial coverage

• Semaglutide peptide profile
• 503A and 503B pharmacy directory
• STEP-1 trial: efficacy data for branded semaglutide

Frequently asked questions

Is compounded semaglutide the same drug as Wegovy or Ozempic?

It is made with the drug in Wegovy and Ozempic (semaglutide, a 31-amino-acid peptide), not the same product. The finished product (concentration, excipients, packaging, dose-delivery device) differs. Brand-name versions are manufactured under FDA-approved NDAs; compounded versions are prepared by state-licensed pharmacies, usually under section 503A, and are not FDA-approved.

Is compounded semaglutide legal?

Yes, within the regulatory framework. In April 2026 FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list (91 FR 23431); comments closed July 30, 2026, and no final decision had been published as of October 15, 2026. Specific formulations identical to commercially available products may be discouraged but are not categorically prohibited.

How do I know if my compounded semaglutide is high quality?

Ask your telehealth provider or pharmacy for the pharmacy name and license number, the API source (and whether it comes from an FDA-registered facility with a drug master file), the pharmacy's 503A or 503B status, and any inspection history (FDA Form 483 observations or state board actions). Reputable providers will answer these questions transparently.

Why is compounded semaglutide so much cheaper?

Compounded versions are cash-pay only and do not include the manufacturer's research and development cost amortization, marketing, or distribution markups built into branded pricing. Compounded semaglutide through telehealth often costs far less than brand: month-to-month examples include $87 (Mondae) and $99 (Eden), read October 15, 2026, and $109 (NexLife, as of November 6, 2026), while Wegovy self-pay through NovoCare is $349 a month for the pen. Compounded versions are not FDA-approved.